You can buy or sell Chiasma and other stocks, options, and ETFs commission-free!
Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The firm's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Waltham, MA. The listed name for CHMA is Chiasma, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 15, After Hours